Акции Tharimmune подешевели на 8,8% amid снижения объема торгов

Tharimmune, Inc. ( NASDAQ:THAR – Get Free Report )’s stock price dropped 8.8% on Thursday. The company traded as low as $2.04 and last traded at $2.08. Approximately 718,254 shares traded hands during mid-day trading, a decline of 51% from the average session volume of 1,476,877 shares. The stock had previously closed at $2.28. Tharimmune Price Performance The company has a 50 day simple moving average of $2.22 and a 200-day simple moving average of $3.10. The firm has a market cap of $86.02 million, a PE ratio of -0.57 and a beta of 1.43. Hedge Funds Weigh In On Tharimmune Several institutional investors and hedge funds have recently made changes to their positions in the business. ARK Investment Management LLC bought a new position in shares of Tharimmune during the fourth quarter valued at about $9,854,000. Clear Street Group Inc. bought a new stake in shares of Tharimmune in the 4th quarter valued at about $5,066,000. Feynman Point Asset Management LLC purchased a new stake in Tharimmune during the 4th quarter valued at about $1,314,000. Marshall Wace LLP bought a new position in Tharimmune during the 4th quarter worth approximately $1,030,000. Finally, Geode Capital Management LLC increased its stake in shares of Tharimmune by 1,102.6% in the fourth quarter. Geode Capital Management LLC now owns 335,923 shares of the company’s stock worth $1,018,000 after buying an additional 307,991 shares during the period. Institutional investors own 1.16% of the company’s stock. Tharimmune Company Profile ( Get Free Report ) Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc for the development of proprietary targeted biologics; and Washington University in St. Featured Stories Five stocks we like better than Tharimmune GitLab’s AI Tools Are Starting to Turn Developer Demand Into Real Revenue GTA VI’s Console Problem Isn’t Take-Two’s Problem Merchants Bancorp’s Rally Is Testing How Much Risk Investors Will Overlook Lululemon’s Earnings Beat Hid a Bigger Problem for Its Turnaround Story Receive News & Ratings for Tharimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tharimmune and related companies with MarketBeat.com's FREE daily email newsletter.